Factors influencing neutralizing antibody titers elicited by coronavirus disease 2019 vaccines

Kung, Yu-An; Huang, San Yuan; Huang, Chung‐Guei; Liu, Kuan‐Ting; Huang, Po-Jung; Yu, Kar-Yee; Yang, Shu-Li; Chen, Chia-Pei; Cheng, Ching-Yun; Lee, Ing-Kit; Lin, Shu‐Min; Chang, Han-Pin; Lin, Yueh-Te; Liu, Yen Chin; Chen, Guang-Wu; Shih, Shin‐Ru

doi:10.1016/j.micinf.2022.105044

Cited by 10 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, in the present study, we observed a relationship between vaccination-induced change in skin temperature and nAB that was a stronger predictor of the 6-month than the 1-month outcome. There are a few other reports examining the association between reactogenicity to SARS-CoV-2 vaccination and subsequent nAB, but interpretability is limited due to low samples sizes (4 to 8 per condition), 22 the analysis only of nAB trajectories over time, 23 which are confounded by absolute levels given that higher decay rates correlate with higher initial levels, 11 and the use of a mixed sample of mRNA and adenoviral vector vaccine recipients. 24 There are several key strengths of our study compared to the previous large studies.…”

Section: Discussionmentioning

confidence: 99%

“…By contrast, the presence of at least one systemic symptom was associated with higher nAB at 12-19 days after dose two (10) and at 54 days after dose three (9). There are a few other reports examining the association between reactogenicity to SARS-CoV-2 vaccination and subsequent nAB, but interpretability is limited due to low samples sizes (4 to 8 per condition) (19), the analysis only of nAB trajectories over time (20), which are confounded by absolute initial levels (11), and the use of a mixed sample of mRNA and adenoviral vector vaccine recipients (21).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The more symptoms the better? Covid-19 vaccine side effects and long-term neutralizing antibody response

Dutcher,

Epel,

Mason

et al. 2023

Preprint

View full text Add to dashboard Cite

Protection against SARS-CoV-2 wanes over time, and booster uptake has been low, in part because of concern about side effects. We examined the relationships between local and systemic symptoms, biometric changes, and neutralizing antibodies (nAB) after mRNA vaccination. Data were collected from adults (n = 364) who received two doses of either BNT162b2 or mRNA-1273. Serum nAB concentration was measured at 1 and 6 months post-vaccination. Daily symptom surveys were completed for six days starting on the day of each dose. Concurrently, objective biometric measurements, including skin temperature, heart rate, heart rate variability, and respiratory rate, were collected. We found that certain symptoms (chills, tiredness, feeling unwell, and headache) after the second dose were associated with increases in nAB at 1 and 6 months post-vaccination, to roughly 140-160% the level of individuals without each symptom. Each additional symptom predicted a 1.1-fold nAB increase. Greater increases in skin temperature and heart rate after the second dose predicted higher nAB levels at both time points, but skin temperature change was more predictive of durable (6 month) nAB response than of short-term (1 month) nAB response. In the context of low ongoing vaccine uptake, our convergent symptom and biometric findings suggest that public health messaging could seek to reframe systemic symptoms after vaccination as desirable.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The more symptoms the better? Covid-19 vaccine side effects and long-term neutralizing antibody response

Dutcher,

Epel,

Mason

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…For each serum sample, the neutralization titer (NT) titer was estimated using the MeDiPro SARS-CoV-2 antibody enzyme-linked immunosorbent assay (Formosa Biomedical Technology Group)according to the manufacturer’s instructions and calculated as previously described 2 L.…”

Section: Methodsmentioning

confidence: 99%

“…Antigenic antibody generation against the virus is a primary component of the immune response and memory evoked by vaccination. The IgG antibody is one of the primary humoral responses of the vaccines 2,3 evoked by COVID-19 vaccines. Many different vaccine platforms (except inactivated vaccines), including genetic vaccines like mRNA and adenovector vaccines, and classical vaccine platforms like protein subunit vaccines, were developed to target the spike (S)-glycoprotein as a single antigen.…”

Section: Introductionmentioning

confidence: 99%

Specific long-term changes in anti-SARS-CoV-2 IgG modifications and antibody functions in mRNA, adenovector, and protein subunit vaccines

Reinig

Kuo

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Different vaccine platforms were developed in 2019 and 2020 to provide immunization for protection against the SARS-CoV-2-caused disease COVID-19. The majority of vaccinated individuals will develop antibodies against SARS-CoV-2. The isotype (subclass) and Fc-glycosylation of IgG antibodies determine their affinity for secondary effector functions. For protein subunit vaccines in COVID-19, the IgG profile of the subclass and glycosylation are unknown. Therefore, we measured the IgG subclass and N-297 Fc glycosylation by ELISA and LC-MS/MS of anti-spike IgG from individuals vaccinated with the Taiwanese protein subunit vaccine Medigen, the mRNA vaccines (BNT, Moderna), and the adenovector Astrazeneca. Samples were taken after the first and second doses. For all vaccine types, the main IgG response was dominated by IgG1 and IgG3 as subclasses. For glycosylation, mRNA vaccines presented with an afucosylation after the first dose and a constant significant higher galactosylation and sialylation than non-mRNA vaccines.

show abstract

“…As prevention for the development of severe disease or infection, most countries employed mass vaccination [ 3 ]⁠. Most individuals infected with SARS-CoV-2 or vaccinated against COVID-19 develop antigen-specific antibodies (immunoglobulins), against the virus as part of their adaptive immune system [ 4 , 5 ]⁠. There are different immunoglobulin classes, including IgM, IgG, IgA, and IgE.…”

Section: Introductionmentioning

confidence: 99%

Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies

Reinig,

Shih

2024

Biomedical Journal

Self Cite

View full text Add to dashboard Cite

Factors influencing neutralizing antibody titers elicited by coronavirus disease 2019 vaccines

Cited by 10 publications

References 27 publications

The more symptoms the better? Covid-19 vaccine side effects and long-term neutralizing antibody response

The more symptoms the better? Covid-19 vaccine side effects and long-term neutralizing antibody response

Specific long-term changes in anti-SARS-CoV-2 IgG modifications and antibody functions in mRNA, adenovector, and protein subunit vaccines

Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies

Contact Info

Product

Resources

About